164 related articles for article (PubMed ID: 34997535)
1. Influenza-induced thrombotic microangiopathy in a patient with cancer on proteasome inhibitor: a diagnostic dilemma.
Hamad CD; Hoelscher ZC; Tchakarov A; Kala J
CEN Case Rep; 2022 Aug; 11(3):321-327. PubMed ID: 34997535
[TBL] [Abstract][Full Text] [Related]
2. Renal and pulmonary thrombotic microangiopathy triggered by proteasome-inhibitor therapy in patient with smoldering myeloma: A renal biopsy and autopsy case report.
Cassol CA; Williams MPA; Caza TN; Rodriguez S
Medicine (Baltimore); 2019 Sep; 98(39):e17148. PubMed ID: 31574818
[TBL] [Abstract][Full Text] [Related]
3. Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition.
Catanese L; Link K; Rupprecht H
BMC Nephrol; 2023 Jun; 24(1):179. PubMed ID: 37337151
[TBL] [Abstract][Full Text] [Related]
4. Thrombotic microangiopathy, cancer, and cancer drugs.
Izzedine H; Perazella MA
Am J Kidney Dis; 2015 Nov; 66(5):857-68. PubMed ID: 25943718
[TBL] [Abstract][Full Text] [Related]
5. Antineoplastic agents and thrombotic microangiopathy.
Garcia G; Atallah JP
J Oncol Pharm Pract; 2017 Mar; 23(2):135-142. PubMed ID: 26854265
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibitor associated thrombotic microangiopathy.
Yui JC; Van Keer J; Weiss BM; Waxman AJ; Palmer MB; D'Agati VD; Kastritis E; Dimopoulos MA; Vij R; Bansal D; Dingli D; Nasr SH; Leung N
Am J Hematol; 2016 Sep; 91(9):E348-52. PubMed ID: 27286661
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-Associated Thrombotic Microangiopathy.
Aklilu AM; Shirali AC
Kidney360; 2023 Mar; 4(3):409-422. PubMed ID: 36706238
[TBL] [Abstract][Full Text] [Related]
8. Thrombotic microangiopathy (TMA) in adult patients with solid tumors: a challenging complication in the era of emerging anticancer therapies.
Font C; de Herreros MG; Tsoukalas N; Brito-Dellan N; Espósito F; Escalante C; Oo TH;
Support Care Cancer; 2022 Oct; 30(10):8599-8609. PubMed ID: 35545722
[TBL] [Abstract][Full Text] [Related]
9. Thrombotic microangiopathy with targeted cancer agents.
Blake-Haskins JA; Lechleider RJ; Kreitman RJ
Clin Cancer Res; 2011 Sep; 17(18):5858-66. PubMed ID: 21813634
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Considerations in H1N1 Influenza-induced Thrombotic Microangiopathy.
Sabulski A; Nehus EJ; Jodele S; Ricci K
J Pediatr Hematol Oncol; 2022 Jan; 44(1):e237-e240. PubMed ID: 33369997
[TBL] [Abstract][Full Text] [Related]
11. Microangiopathy in Cancer: Causes, Consequences, and Management.
Thomas MR; Scully M
Cancer Treat Res; 2019; 179():151-158. PubMed ID: 31317486
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
13. Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature.
Monteith BE; Venner CP; Reece DE; Kew AK; Lalancette M; Garland JS; Shepherd LE; Pater JL; Hay AE
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e791-e800. PubMed ID: 32807717
[TBL] [Abstract][Full Text] [Related]
14. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Hobeika L; Self SE; Velez JC
BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524
[TBL] [Abstract][Full Text] [Related]
15. Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review.
Jindal N; Jandial A; Jain A; Lad D; Prakash G; Khadwal A; Nada R; Sethi J; Ahluwalia J; Malhotra P
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):426-431. PubMed ID: 32735793
[TBL] [Abstract][Full Text] [Related]
16. Thrombotic Microangiopathy in Cancer.
Weitz IC
Semin Thromb Hemost; 2019 Jun; 45(4):348-353. PubMed ID: 31041804
[TBL] [Abstract][Full Text] [Related]
17. Chronic Microangiopathy Due to DCR-MYC, a Myc-Targeted Short Interfering RNA.
Miller AJ; Chang A; Cunningham PN
Am J Kidney Dis; 2020 Apr; 75(4):513-516. PubMed ID: 31866228
[TBL] [Abstract][Full Text] [Related]
18. [Thrombotic microangiopathy and cancer].
Kheder El-Fekih R; Deltombe C; Izzedine H
Nephrol Ther; 2017 Nov; 13(6):439-447. PubMed ID: 28774729
[TBL] [Abstract][Full Text] [Related]
19. Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange.
Sullivan MR; Danilov AV; Lansigan F; Dunbar NM
J Clin Apher; 2015 Oct; 30(5):308-10. PubMed ID: 25413611
[TBL] [Abstract][Full Text] [Related]
20. Thrombotic microangiopathy associated with Valproic acid toxicity.
Hebert SA; Bohan TP; Erikson CL; Swinford RD
BMC Nephrol; 2017 Aug; 18(1):262. PubMed ID: 28774273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
